Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis

The presented review searched for articles in the databases PubMed, Web of Science, Scopus, Google Scholar, eLibrary (2002-2022) and assessed the immunogenicity of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in adult patients with rheumatoid arthritis (RA), receiving various antirheuma...

Full description

Saved in:
Bibliographic Details
Main Authors: B. Ts. Batozhargalova, N. A. Sagatbayeva, G. M. Abdullayeva, Sh. K. Bytyrkhanov, I. L. Solovеva, M. P. Kostinov, A. D. Shmitko
Format: Article
Language:Russian
Published: Journal Infectology 2024-09-01
Series:Журнал инфектологии
Subjects:
Online Access:https://journal.niidi.ru/jofin/article/view/1660
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849241100465733632
author B. Ts. Batozhargalova
N. A. Sagatbayeva
G. M. Abdullayeva
Sh. K. Bytyrkhanov
I. L. Solovеva
M. P. Kostinov
A. D. Shmitko
author_facet B. Ts. Batozhargalova
N. A. Sagatbayeva
G. M. Abdullayeva
Sh. K. Bytyrkhanov
I. L. Solovеva
M. P. Kostinov
A. D. Shmitko
author_sort B. Ts. Batozhargalova
collection DOAJ
description The presented review searched for articles in the databases PubMed, Web of Science, Scopus, Google Scholar, eLibrary (2002-2022) and assessed the immunogenicity of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in adult patients with rheumatoid arthritis (RA), receiving various antirheumatic drugs. The results of this review indicated sufficient immunogenicity of PPV23 in RA patients receiving monotherapy with various biological drugs (bDMARDs) (TNFα inhibitors, IL6 receptor inhibitors, T-lymphocyte costimulation blockers), targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), and glucocorticoids (GC) in medium and low doses. Monotherapy with methotrexate (MTX), rituximab and combination therapy with bDMARDs +MTX, tsDMARDs+MTX in RA patients reduced the postvaccination pneumococcal response. IgG AT generated in response to PPV23 injection shown functional activity even in RA patients whose antibodies were either lowered in patients receiving MTX or were not detectable at protective values following bDMARD therapy. The potential for pneumococcus antibody production in RA patients receiving therapy with disease-modifying antirheumatic drugs (DMARDs), tsDMARDs and bDMARDs, was concluded. Vaccination against pneumococcal infection should be advised prior to starting therapy due to the likelihood of low antibody levels developing during rituximab treatment.
format Article
id doaj-art-4503875ccf024d85884d388111b7a372
institution Kabale University
issn 2072-6732
language Russian
publishDate 2024-09-01
publisher Journal Infectology
record_format Article
series Журнал инфектологии
spelling doaj-art-4503875ccf024d85884d388111b7a3722025-08-20T04:00:18ZrusJournal InfectologyЖурнал инфектологии2072-67322024-09-01163364410.22625/2072-6732-2024-16-3-36-441160Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritisB. Ts. Batozhargalova0N. A. Sagatbayeva1G. M. Abdullayeva2Sh. K. Bytyrkhanov3I. L. Solovеva4M. P. Kostinov5A. D. Shmitko6Research Institute of Vaccines and Sera named after I.I. MechnikovKazakh National Medical University named after S.D. AsfendivarovKazakh National Medical University named after S.D. AsfendivarovKazakh National Medical University named after S.D. AsfendivarovUlyanovsk State UniversityResearch Institute of Vaccines and Sera named after I.I. Mechnikov; First Moscow State Medical University named after I.M. Sechenov (Sechenov University)Research Institute of Vaccines and Sera named after I.I. MechnikovThe presented review searched for articles in the databases PubMed, Web of Science, Scopus, Google Scholar, eLibrary (2002-2022) and assessed the immunogenicity of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in adult patients with rheumatoid arthritis (RA), receiving various antirheumatic drugs. The results of this review indicated sufficient immunogenicity of PPV23 in RA patients receiving monotherapy with various biological drugs (bDMARDs) (TNFα inhibitors, IL6 receptor inhibitors, T-lymphocyte costimulation blockers), targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), and glucocorticoids (GC) in medium and low doses. Monotherapy with methotrexate (MTX), rituximab and combination therapy with bDMARDs +MTX, tsDMARDs+MTX in RA patients reduced the postvaccination pneumococcal response. IgG AT generated in response to PPV23 injection shown functional activity even in RA patients whose antibodies were either lowered in patients receiving MTX or were not detectable at protective values following bDMARD therapy. The potential for pneumococcus antibody production in RA patients receiving therapy with disease-modifying antirheumatic drugs (DMARDs), tsDMARDs and bDMARDs, was concluded. Vaccination against pneumococcal infection should be advised prior to starting therapy due to the likelihood of low antibody levels developing during rituximab treatment.https://journal.niidi.ru/jofin/article/view/1660immunogenicity23-valent polysaccharide pneumococcal vaccinerheumatoid arthritistherapy
spellingShingle B. Ts. Batozhargalova
N. A. Sagatbayeva
G. M. Abdullayeva
Sh. K. Bytyrkhanov
I. L. Solovеva
M. P. Kostinov
A. D. Shmitko
Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis
Журнал инфектологии
immunogenicity
23-valent polysaccharide pneumococcal vaccine
rheumatoid arthritis
therapy
title Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis
title_full Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis
title_fullStr Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis
title_full_unstemmed Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis
title_short Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis
title_sort immunogenicity of pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis
topic immunogenicity
23-valent polysaccharide pneumococcal vaccine
rheumatoid arthritis
therapy
url https://journal.niidi.ru/jofin/article/view/1660
work_keys_str_mv AT btsbatozhargalova immunogenicityofpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis
AT nasagatbayeva immunogenicityofpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis
AT gmabdullayeva immunogenicityofpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis
AT shkbytyrkhanov immunogenicityofpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis
AT ilsoloveva immunogenicityofpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis
AT mpkostinov immunogenicityofpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis
AT adshmitko immunogenicityofpneumococcalpolysaccharidevaccineinpatientswithrheumatoidarthritis